Paper Details

  1. Home
  2. Paper Details

Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk.

Author: HeintelDaniel, NösslingerThomas, StaberPhilipp, SteurerMichael, StühlingerMarkus C, WeltermannAnsgar

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Ibrutinib is a Bruton's tyrosine kinase inhibitor used to treat B-cell malignancies. This abstract discusses the management of specific side effects associated with ibrutinib treatment, including atrial fibrillation, bleeding, and hypertension.
Paper Details　
Original Abstract of the Article :
Ibrutinib is the first clinically approved inhibitor of Bruton's tyrosine kinase, an enzyme that is essential for survival and proliferation of B‑cells by activating the B‑cell receptor signalling pathway. Ibrutinib has been shown to be highly effective in B‑cell malignancies in clinical trials and ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035304/

データ提供：米国国立医学図書館（NLM）

Ibrutinib: A Powerful Weapon Against B-cell Malignancies, But With a Twist

This study ventures into the world of ibrutinib, a groundbreaking drug used to treat B-cell malignancies, a group of cancers that affect B-cells, a type of white blood cell. Imagine ibrutinib as a skilled archer who targets and destroys the rogue B-cells, restoring balance to the immune system. This study explores the potential benefits and risks of using ibrutinib, especially in patients with atrial fibrillation or other cardiovascular concerns.

Ibrutinib: A Powerful Tool But With Potential Cardiovascular Considerations

The authors reviewed the data from [research methodology] to assess the use of ibrutinib in patients with atrial fibrillation or elevated cardiovascular risk. They highlight that ibrutinib can be a valuable treatment option but recommend careful monitoring and management of cardiovascular risks.

Navigating the Landscape of Ibrutinib Therapy: A Balanced Approach

This study emphasizes the importance of a tailored approach to ibrutinib therapy, carefully balancing the potential benefits with the potential cardiovascular risks. It encourages clinicians to be aware of these risks and to implement appropriate monitoring and management strategies to ensure patient safety.

Dr. Camel's Conclusion

This study reminds us that even the most effective medications can have unforeseen side effects. The use of ibrutinib in patients with cardiovascular conditions requires a careful balance between the drug's potential benefits and the potential risks, showcasing the importance of individualized care in optimizing treatment outcomes.
Date :
  1. Date Completed 2020-09-17
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

31414181

DOI: Digital Object Identifier

PMC7035304

Related Literature

Article Analysis
・Side Effects of ibrutinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.